

Rec'd PCT/PTO 16 DEC 2004

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
9 December 2004 (09.12.2004)

PCT

(10) International Publication Number  
WO 2004/106326 A1

(51) International Patent Classification<sup>7</sup>: C07D 401/14,  
A61K 31/506

(21) International Application Number:  
PCT/IN2003/000206

(22) International Filing Date: 2 June 2003 (02.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(71) Applicant (for all designated States except US): HETERO  
DRUGS LIMITED [IN/IN]; Hetero House, 8-3-166/7/1,  
Erragadda, Hyderabad 500 018, Andhra Pradesh (IN).

(72) Inventors; and

(75) Inventors/Applicants (for US only):  
PARTHASARADHI REDDY, Bandi [IN/IN]; Hetero  
House, 8-3-166/7/1, Erragadda, Hyderabad 500 018,  
Andhra Pradesh (IN). RATHNAKAR REDDY, Kura  
[IN/IN]; Hetero Drugs Limited (R & D), Plot No. B-80  
& 81, A.P.I.E., Balanagar, Hyderabad 500 018, Andhra  
Pradesh (IN). RAJI REDDY, Rapolu [IN/IN]; Hetero  
Drugs Limited (R & D), Plot No. B-80 & 81, A.P.I.E.,  
Balanagar, Hyderabad 500 018, Andhra Pradesh (IN).  
MURALIDHARA REDDY, Dasari [IN/IN]; Hetero  
Drugs Limited (R & D), Plot No. B-80 & 81, A.P.I.E.,  
Balanagar, Hyderabad 500 018, Andhra Pradesh (IN).  
SUBASH CHANDER REDDY, Kestreddy [IN/IN];  
Hetero Drugs Limited (R & D), Plot No. B-80 & 81,  
A.P.I.E., Balanagar, Hyderabad 500 018, Andhra Pradesh  
(IN).

(81) Designated States (national): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,

GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD,  
SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,  
UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,  
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,  
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

#### Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted  
a patent (Rule 4.17(ii)) for the following designations AE,  
AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH,  
CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI,  
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG,  
KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK,  
MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU,  
SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG,  
UZ, VC, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian  
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European  
patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR,  
GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR),  
OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,  
ML, MR, NE, SN, TD, TG)
- of inventorship (Rule 4.17(iv)) for US only

#### Published:

- with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL POLYMORPHS OF IMATINIB MESYLATE

(57) Abstract: The present invention relates to novel polymorphs of imatinib mesylate, to processes for their preparation and to pharmaceutical compositions containing them.

WO 2004/106326 A1

NOVEL POLYMORPHS OF IMATINIB MESYLATEFIELD OF THE INVENTION

5


The present invention relates to novel polymorphs of imatinib mesylate, to processes for their preparation and to pharmaceutical compositions containing them.

10

BACKGROUND OF THE INVENTION

Imatinib, chemically 4-[(4-methyl-1-piperazinyl)methyl]-N-[4-methyl-3-[[4-(3-pyridinyl)-2-pyrimidinyl]amino]phenyl]benzamide, is represented by the following structure:

15



20

Imatinib and its salts are anti-tumor agents, which were disclosed in US 5,521,184. Two crystalline modifications ( $\alpha$ -form and  $\beta$ -form) of imatinib mesylate were mentioned in WO 99/03854.

WO 99/03854 mentioned amorphous imatinib mesylate, but it did not make any reference to hydrate of imatinib mesylate.

25

We have discovered a stable novel crystalline form of imatinib mesylate. The novel form is at least as stable as the reported forms,  $\alpha$ - and  $\beta$ -forms. The novel crystalline form is stable over the time and has good flow properties and so, the novel crystalline form is suitable for formulating imatinib mesylate.

30

Amorphous forms of pharmaceutical products are usually known to have better dissolution properties than their crystalline forms. If amorphous form of a pharmaceutical product is stable enough, it can be formulated to a pharmaceutical composition having good dissolution properties.

We have discovered hydrate of imatinib mesylate.

We have also discovered a sufficiently stable non-hygroscopic amorphous form of imatinib mesylate hydrate. So, amorphous form of imatinib mesylate hydrate can be utilized to prepare stable pharmaceutical dosage forms  
5 having good dissolution properties.

One object of the present invention is to provide a stable novel crystalline form of imatinib mesylate, hydrate of imatinib mesylate and amorphous imatinib mesylate hydrate.

Another object of the present invention is to provide processes for  
10 preparing the novel crystalline form of imatinib mesylate, hydrate of imatinib mesylate and amorphous imatinib mesylate hydrate.

Still another object of the present invention is to provide pharmaceutical compositions containing the novel crystalline form of imatinib mesylate, hydrate of imatinib mesylate and amorphous imatinib mesylate hydrate.

15

#### DETAILED DESCRIPTION OF THE INVENTION

As used herein, room temperature refers to about 25°C to 30°C.

In accordance with the present invention, there is provided a novel  
20 crystalline form of imatinib mesylate, designated as form H1, characterized by an x-ray powder diffraction spectrum having peaks expressed as 2θ at about 9.9, 11.1, 16.3, 17.3, 18.1, 19.1, 19.6, 20.3, 21.1, 21.9, 23.2, 23.6, 24.2, 24.9, 25.6, 26.0, 27.3, 27.9, 28.9, 29.4, 30.4 and 30.5 degrees. Figure 1 shows typical form H1 x-ray powder diffraction spectrum.

25 In accordance with the present invention, a process is provided for preparation of imatinib mesylate form H1. Imatinib free base is dissolved in a chlorinated solvent, methanesulfonic acid is added and imatinib mesylate form H1 is isolated.

30 Examples of chlorinated solvents are chloroform, methylene dichloride, ethylene dichloride and a mixture thereof. Preferable solvents are chloroform and methylene dichloride.

Imatinib free base may be dissolved in the chlorinated solvents at room temperature or at an elevated temperature.

The quantity of methanesulfonic acid per mole of imatinib free base is not critical but preferably at least one mole of methanesulfonic acid per mole of imatinib free base is used to obtain maximum yield of imatinib mesylate.

5 Methanesulfonic acid can be added to the solution of imatinib free base in chlorinated solvent preferably between about 5°C to reflux temperature, more preferably between room temperature to reflux temperature. Most preferably, methanesulfonic acid is added at room temperature.

Then, the precipitated imatinib mesylate form H1 is collected by filtration or centrifugation.

10 In accordance with the present invention, an another process is provided for preparation of imatinib mesylate form H1. A mixture of imatinib mesylate and a chlorinated solvent is stirred for about 10 hours to 48 hours and imatinib mesylate form H1 is isolated.

15 Examples of chlorinated solvents are chloroform, methylene dichloride, ethylene dichloride and a mixture thereof. Preferable solvents are chloroform and methylene dichloride.

Imatinib mesylate in a previously known crystalline or amorphous form may be used in the process. Imatinib mesylate hydrate obtained by the process described below may also be used. Particularly  $\alpha$ -form,  $\beta$ -form or amorphous  
20 imatinib mesylate may be used.

Preferably, the mixture of imatinib mesylate and a chlorinated solvent is stirred between about 5°C to reflux temperature, more preferably between room temperature to reflux temperature, for about 24 hours to 48 hours.

Then imatinib mesylate form H1 is collected by filtration or centrifugation.

25 In accordance with the present invention, there is provided a novel hydrate of imatinib mesylate. The water content of the hydrate of imatinib mesylate is between 2.0 to 3.2% by weight of hydrate of imatinib mesylate, typically between 2.2 to 2.9% by weight of hydrate of imatinib mesylate.

The amorphous form of imatinib mesylate hydrate, designated as  
30 amorphous imatinib mesylate hydrate, is characterized by having broad x-ray diffraction spectrum as in figure 2.

In accordance with the present invention, a process is provided for preparation of imatinib mesylate hydrate.

Imatinib mesylate hydrate is prepared by dissolving imatinib mesylate in a mixture of a suitable solvent and water and removing the solvents from the solution.

Imatinib mesylate in a crystalline or amorphous form may be used in the process. Particularly  $\alpha$ -form,  $\beta$ -form or amorphous imatinib mesylate may be used.

The suitable solvent is selected from the group consisting of alcohols, e.g., methanol, ethanol, isopropyl alcohol; ketones, e.g., acetone; acetonitrile; and a mixture thereof.

The solvent may be removed from the solution by vacuum drying or spray drying to give amorphous imatinib mesylate hydrate. The drying time and the drying temperature depend on the solvent used in the process. For example if the solvent is methanol, the solvent and water can be removed at about 50°C for about 9 hours.

Imatinib free base and imatinib mesylate obtained by the previously known methods may be used in the above processes.

In accordance with the present invention, there is provided a pharmaceutical composition comprising imatinib mesylate form H1 and a pharmaceutically acceptable carrier or diluent.

In accordance with the present invention, there is provided a pharmaceutical composition comprising imatinib mesylate hydrate and a pharmaceutically acceptable carrier or diluent. Amorphous imatinib mesylate hydrate may also be used in the composition.

25

#### BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1 is a x-ray powder diffraction spectrum of imatinib mesylate form H1.

Figure 2 is a x-ray powder diffraction spectrum of amorphous imatinib mesylate hydrate.

30

x-Ray powder diffraction spectrum was measured on a Bruker axs D8 advance x-ray powder diffractometer having a copper-K $\alpha$  radiation.

The invention will now be further described by the following examples, which are illustrative rather than limiting.

## Example 1

Imatinib free base (5.0 gm) is dissolved in chloroform (50 ml) at room temperature and then methanesulfonic acid (0.75 ml) is added. The contents are stirred for 5 hours at room temperature and separated crystals are filtered and dried to give 5.0 gm of imatinib mesylate form H1.

## Example 2.

The mixture of Imatinib mesylate ( $\alpha$ -form, 5.0 gm) and chloroform (150 ml) is heated to 50°C and stirred for 36 hours at this temperature. Then the contents are cooled to 25°C, maintained for 5 hours at room temperature and filtered and dried to give 4.5 gm of imatinib mesylate form H1.

## Example 3

The mixture of Imatinib mesylate ( $\beta$ -form, 5.0 gm) and chloroform (150 ml) is heated to 50°C and stirred for 36 hours at this temperature. Then the contents are cooled to 25°C, maintained for 5 hours at room temperature and filtered and dried to give 4.3 gm of imatinib mesylate form H1.

## Example 4

Imatinib free base (5.0 gm) is dissolved in methylene dichloride (50 ml) at room temperature and then methanesulfonic acid (0.75 ml) is added. The contents are stirred for 5 hours at room temperature and filtered and dried to give 4.9 gm of imatinib mesylate form H1.

## Example 5

The mixture of Imatinib mesylate (5.0 gm) and methylene dichloride (150 ml) is heated to 50°C and stirred for 5 hours at this temperature. Then the contents are cooled to 25°C, maintained for 25 hours at room temperature and filtered to give 4.6 gm of imatinib mesylate form H1

## Example 6

Imatinib mesylate form H1 (3.5 gm) is dissolved in a mixture of methanol (25 ml) and water (5.0 ml) at room temperature. The solution is subjected to

vacuum drying at about 50°C for 9 hours to give 3.0 gm of amorphous imatinib mesylate hydrate.

#### Example 7

- 5           Example 6 is carried out using imatinib mesylate ( $\alpha$ -form) instead of imatinib mesylate form H1 to give imatinib mesylate hydrate.

#### Example 8

- 10           Example 6 is carried out by subjecting the solution to spray drying instead of vacuum drying to give amorphous imatinib mesylate hydrate.

We claim:

1. A crystalline imatinib mesylate form H1, characterized by an x-ray powder diffraction spectrum having peaks expressed as  $2\theta$  at about 9.9, 11.1, 16.3,  
5 17.3, 18.1, 19.1, 19.6, 20.3, 21.1, 21.9, 23.2, 23.6, 24.2, 24.9, 25.6, 26.0, 27.3, 27.9, 28.9, 29.4, 30.4 and 30.5 degrees.
2. A crystalline imatinib mesylate form H1 as defined in claim 1, further characterized by a x-ray powder diffraction spectrum as in figure 1.
3. A process for preparation of imatinib mesylate form H1 as defined in claim 1,  
10 which comprises the steps of:
  - a) dissolving imatinib free base in a chlorinated solvent;
  - b) adding methanesulfonic acid; and
  - c) isolating imatinib mesylate form H1 by filtration or centrifugation;wherein the chlorinated solvents is selected from chloroform, methylene  
15 dichloride, ethylene dichloride and a mixture thereof.
4. A process according to claim 3, wherein the chlorinated solvent is chloroform.
5. A process according to claim 3, wherein the chlorinated solvent is methylene dichloride.
- 20 6. A process for preparation of imatinib mesylate form H1 as defined in claim 1, which comprises the steps of:
  - a) mixing imatinib mesylate and a chlorinated solvent; and
  - b) isolating imatinib mesylate form H1 by filtration or centrifugation;wherein the chlorinated solvent is selected from chloroform, methylene  
25 dichloride, ethylene dichloride and a mixture thereof.
7. A process according to claim 6, wherein the chlorinated solvent is chloroform.
8. A process according to claim 6, wherein the chlorinated solvent is methylene dichloride.
- 30 9. Imatinib mesylate hydrate.
10. Imatinib mesylate hydrate of claim 9, wherein water content of the hydrate of imatinib mesylate is between 2.0 to 3.2% by weight of hydrate of imatinib mesylate.



11. Imatinib mesylate hydrate of claim 10, wherein water content of the hydrate of imatinib mesylate is between 2.2 to 2.9% by weight of hydrate of imatinib mesylate.
12. Imatinib mesylate hydrate of claim 11, wherein water content of the hydrate of imatinib mesylate is about 2.5% by weight of hydrate of imatinib mesylate.
13. A process for preparation of imatinib mesylate hydrate of claim 9, which comprises the steps of:
- a) dissolving imatinib mesylate in a mixture of a suitable solvent and water;
  - b) removing the solvents from the solution formed in (a) either by vacuum drying or by spray drying;
- wherein the suitable solvent is selected from alcohols, ketones, acetonitrile and a mixture thereof.
14. A process according to claim 13, wherein the solvent is removed by vacuum drying.
15. A process according to claim 13, wherein the solvent is removed by spray drying.
16. A process according to claim 13, wherein the alcohol is selected from methanol, ethanol and isopropyl alcohol; and the ketone is acetone.
17. A process according to claim 13, wherein the suitable solvent is methanol.
18. A process according to claim 13, wherein the suitable solvent is ethanol.
19. Amorphous imatinib mesylate hydrate.
20. Amorphous imatinib mesylate hydrate of claim 19 characterized by a x-ray powder diffraction spectrum as in figure 2.
21. Amorphous imatinib mesylate hydrate of claim 19, produced according to the process described in claim 13.
22. A pharmaceutical composition comprising imatinib mesylate form H1 of claim 1 and a pharmaceutically acceptable carrier or diluent.
23. A pharmaceutical composition comprising imatinib mesylate hydrate of claim 9 and a pharmaceutically acceptable carrier or diluent.
24. A pharmaceutical composition comprising amorphous imatinib mesylate hydrate of claim 19 and a pharmaceutically acceptable carrier or diluent.

Fig. 1/2





Fig. 2/2



## INTERNATIONAL SEARCH REPORT

International application No.  
PCT/IN 03/00206-0

## CLASSIFICATION OF SUBJECT MATTER

IPC<sup>7</sup>: C07D 401/14, A61K 31/506

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC<sup>7</sup>: C07D, A61J

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

REGISTRY, CAPLUS

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99/03854 A (NOVARTIS ERFIND VERWALT GMBH; NOVARTIS AG) 28 January 1999 (28.01.99) ; cited in the application <i>the whole document.</i>	1-24
A	US 5521184 A (CIBA GEIGY CORP; ZIMMERMANN JUERG) 28 May 1996 (28.05.96) ; cited in the application. <i>example 21.</i>	1-24

☐ Further documents are listed in the continuation of Box C.☒ See patent family annex.

\* Special categories of cited documents:

„A“ document defining the general state of the art which is not considered to be of particular relevance

„E“ earlier application or patent but published on or after the international filing date

„L“ document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

„O“ document referring to an oral disclosure, use, exhibition or other means

„P“ document published prior to the international filing date but later than the priority date claimed

„T“ later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

„X“ document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

„Y“ document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

„&amp;“ document member of the same patent family

Date of the actual completion of the international search

13 February 2004 (13.02.2004)

Date of mailing of the international search report

10 March 2004 (10.03.2004)

Name and mailing address of the ISA/AT

Austrian Patent Office

Dresdner Straße 87, A-1200 Vienna

Facsimile No. 1/53424/535

Authorized officer

MÜLLER-HIEL R.

Telephone No. 1/53424/434

**INTERNATIONAL SEARCH REPORT**

Information on patent family members

International application No.

PCT/IN 03/00206-0

Patent document cited in search report			Publication date		Patent family member(s)	Publication date
US	A	5521184			CY A 2229	2003-04-18
					LU A 90908	2003-04-30
					DE I 10299016I	2002-08-29
					NO A 931283	1993-10-04
					SK B 280620B	2000-05-16
					KR B 261366	2000-08-01
WO	A	9903854			DK T 998473T	2004-02-02
					CN B 1134429B	2004-01-14
					ID A 24093	2000-07-06
					DE D 69818674D	2003-11-06
					RU C 2208012	2003-07-10
					AT T 251152T	2003-10-15